1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
HPGC Renmintongtai Pharmaceutical Corporation

HPGC Renmintongtai Pharmaceutical Corporation

600829.SS
HPGC Renmintongtai Pharmaceutical CorporationCN flagShanghai Stock Exchange
8.00
CNY
-0.33
- -
4.64BMarket Cap
HPGC Renmintongtai Pharmaceutical Corporation
600829.SS
(Shanghai Stock Exchange)

Recent

price

8.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
5.18
6.22
7.02
5.46
15.54
15.37
15.53
13.81
12.17
14.41
13.78
16.06
16.63
17.92
17.33
17.9
13.52
Revenue per Share
0.58
0.69
0.63
0.01
0.32
0.24
0.39
0.44
0.44
0.46
0.25
0.48
0.46
0.5
0.37
0.23
0.17
Basic EPS, GAAP
0.19
-0.34
0.33
-0.33
0.68
0.51
0.04
0.23
0.62
-0.72
-0.04
-0.42
0.52
0.53
0.19
0.49
-0.02
Free Cash Flow per Basic Share
0.29
0.19
0.04
0.03
0.19
0.02
0.01
0.51
0.52
0.02
0.01
0.06
0.05
0.04
0.28
0.03
0.01
Dividend per Share
1.8
2.44
3.01
2.92
3.81
2.45
2.79
2.7
2.61
3.04
3.25
3.61
4.06
4.56
4.79
5.02
5.1
Book Value per Share
2.79
3.05
3.7
3.54
4.85
2.4
2.79
2.73
2.68
3.14
3.38
3.74
4.19
4.7
4.92
5.15
5.24
Tangible Book Value per Share
580
580
580
582
580
580
580
580
580
580
581
580
580
580
580
580
580
Basic Weighted Avg Shares
3,005
3,606
4,068
3,177
9,011
8,909
9,006
8,009
7,055
8,354
8,005
9,315
9,641
10,390
10,048
10,379
7,839
Sales/Revenue/Turnover
12.44
12.22
11.25
2.03
4.06
3.44
3.94
4.5
5.03
4.91
3.29
4.53
3.91
4.27
3.23
2.8
2.82
Operating Margin (%)
73
83
85
87
109
51
32
30
29
27
25
60
64
60
62
59
- -
Depreciation Expense
334
399
364
6
187
139
225
254
258
267
145
277
264
292
213
134
97
Net Income, GAAP
19.21
19.99
23.24
113.83
31.05
42.22
25.81
25.21
25.41
26.01
34.02
22.89
23.45
25.71
26.22
29.39
30.91
Effective Tax Rate (%)
11.11
11.05
8.95
0.2
2.08
1.56
2.49
3.17
3.65
3.2
1.81
2.98
2.74
2.81
2.12
1.29
1.24
Profit Margin (%)
571
663
1,000
923
1,563
1,037
1,286
1,240
1,237
1,513
1,616
1,829
2,115
2,404
2,553
2,678
2,719
Working Capital
6
6
4
3
3
- -
- -
- -
- -
- -
34
60
38
29
30
28
24
LT Debt
1,739
1,936
2,306
2,215
2,987
1,423
1,648
1,612
1,580
1,847
1,992
2,199
2,458
2,751
2,881
3,015
3,063
Total Equity
16.34
15.75
13.21
-0.33
8.04
6.86
16.85
16.11
15.78
15.53
7.26
10.99
8.27
9.12
6.6
5.74
3.97
Return on Invested Capital (%)
26.06
25.24
18.62
0.86
8.44
6.86
13.94
14.76
15.66
14.22
6.83
10.57
8.47
8.57
6.38
4.13
2.95
Return on Capital (%)
32.79
32.49
23.07
0.38
9.59
7.65
14.76
15.97
16.75
16.32
7.96
13.92
11.88
11.68
7.86
4.71
3.36
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
704
731
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
28
24
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
580
580
Market Capitalization
4,572
6,265
5,907

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
6,693
6,870
Cash, Cash Equivalents & STI
- -
1,235
884
Accounts Receivable, Net
- -
3,854
4,305
Inventories
- -
1,230
1,282
Total Current Liabilities
- -
4,015
4,150
Payables & Accruals
- -
- -
- -
ST Debt
- -
704
731
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.99%
8.69%
4.65%
Free Cash Flow
107.48%
167.15%
163.34%
Net Income, GAAP
6.68%
6.5%
-37.24%
Sales/Revenue/Turnover
2%
5.53%
3.29%
Total Cash Common Dividend
659.33%
233.43%
-87.48%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,598
2,387
2,693
2,370
10,048
2025
2,667
2,483
- -
2,533
10,379
2026
2,824
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.14
- -
- -
- -
0.37
2025
0.08
- -
- -
- -
0.23
2026
0.08
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
- -
- -
- -
0.28
2025
0.02
- -
- -
- -
0.03
2026
0.01
- -
- -
- -
- -
Similar Companies
PT Industri Jamu dan Farmasi Sido Muncul Tbk (SIDO.JK)
CanaQuest Medical Corp. (CANQF)
Aarti Drugs Limited (AARTIDRUGS.NS)
Global Hemp Group Inc. (GHG.CN)
Procaps Group S.A. (PROC)
Curative Biosciences, Inc. (CBDX)
Business
HPGC Renmintongtai Pharmaceutical Corporation (600829.SS), formerly Harbin Pharmaceutical Group Sanjing Pharmaceutical Shareholding Co., Ltd., engages principally in the wholesale and retail of pharmaceutical products in China. The company offers Chinese and Western patent medicines, Chinese herbal medicines and slices, chemical preparations, antibiotics, biological products, biochemical drugs, medical devices, health products, tonic health supplements, daily necessities, and cosmetics; it also provides pharmaceutical logistics services including warehousing and distribution, hospital services encompassing medical treatment, scientific research, prevention, health care, rehabilitation, hemodialysis, and kidney disease treatment, as well as medical and commercial distribution, third-terminal sales, and operation of Chinese medicine and outpatient clinics. Founded in 1950 and headquartered at No. 418 Haiyao Road, Harbin, China, it operates nearly 400 retail stores including flagship, regional center, community, and hospital-adjacent outlets serving over 2.7 million members, alongside two major wholesale divisions with the largest provincial drug distribution network and Heilongjiang's first modern pharmaceutical logistics center spanning 150,000 square meters. As a subsidiary of Harbin Pharmaceutical Group Co., Ltd., it maintains operations through e-commerce platforms, direct store chains, online B2C, O2O, and WeChat mini-programs, targeting diverse consumers with integrated batch-retail, medicine-healthcare, and procurement-sales-warehousing-distribution synergies. In recent developments, the company reported a projected net profit reduction of 21.1 million yuan for 2024 attributable to net disposal gains, amid broader industry consolidation and regulatory pressures promoting higher market concentration in pharmaceutical retail.